| Título | Role of maraviroc and/or rapamycin in the liver of IL10 KO mice with frailty syndrome |
|---|---|
| Autores | Perez-Martinez, Laura , Romero, Lourdes , VERDUGO SIVIANES, EVA MARÍA, Munoz-Galvan, Sandra , Rubio-Mediavilla, Susana , Amiama-Roig, Ana , Carnero, Amancio , Blanco, Jose-Ramon |
| Publicación externa | Si |
| Medio | PLoS ONE |
| Alcance | Article |
| Naturaleza | Científica |
| Cuartil JCR | 1 |
| Cuartil SJR | 1 |
| Fecha de publicacion | 10/01/2024 |
| ISI | 001153638300031 |
| DOI | 10.1371/journal.pone.0286201 |
| Abstract | Cellular senescence and low-grade inflammation favor the acceleration of aging. The liver is an essential metabolic organ because changes related to its function are related to age-related diseases. The objective of this study was to evaluate the effects of maraviroc (MVC) and/or rapamycin (RAPA) on liver tissue in an experimental model of frailty syndrome in mice, since MVC and RAPA are two molecules able to decrease CCR5 expression, which is overexpressed in patients with frailty. Methods: Eighty male homozygous IL10KO mice were randomly assigned to one of 4 groups (n = 20): i) IL10KO group; ii) MVC group, iii) RAPA group, and iv) MVC-RAPA group. Liver samples were analyzed. Gene expression quantification and western blotting were also performed. The proinflammatory cytokines IL-6 and IL-18 were decreased in MVC and MVC/RAPA groups, IL-12 was decreased in RAPA and MVC/RAPA groups and TNF-alpha was decreased in all therapeutic groups. P21 was decreased in RAPA and MVC/RAPA groups, Galactosidase beta-1, was also significantly reduced in all therapeutic groups, as were NF-kB1, NF-kB2 and STAT3. In all groups, mTOR and CCL5 were significantly reduced. CCR5 expression was decreased in the MVC and MVC/RAPA groups. Conclusion: MVC and RAPA may protect against some factors involved in liver aging. More studies will be necessary to verify their clinical applications. |
| Miembros de la Universidad Loyola |